Amgen Inc. (BKK:AMGN06)
Thailand · Delayed Price · Currency is THB | Market Cap | 6.19T +7.6% |
| Revenue (ttm) | 1.16T +10.0% |
| Net Income | 243.18B +88.5% |
| EPS | 448.77 +88.2% |
| Shares Out | n/a |
| PE Ratio | 25.44 |
| Forward PE | 15.70 |
| Dividend | 0.02 (0.58%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 1,656 |
| Average Volume | 21,778 |
| Open | 2.880 |
| Previous Close | 2.880 |
| Day's Range | 2.860 - 2.920 |
| 52-Week Range | 2.600 - 3.100 |
| Beta | n/a |
| RSI | 51.85 |
| Earnings Date | Apr 30, 2026 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.
Financial numbers in USD Financial StatementsNews
Global pharma companies that have publicly announced Trump drug pricing agreements
U.S. President Donald Trump secured agreements with 16 major pharmaceutical companies to bring U.S. prescription drug prices in line with those paid in other developed nations in exchange for three-ye...
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a global clinical trial collaboration with Amgen Inc. (NASDAQ: AMGN) to evaluate Zai Lab's inve...
FDA Says Amgen's Tavneos Linked to Liver Injuries, Deaths
The FDA said it has identified 76 cases of drug-induced liver injuries with reasonable evidence of being causally linked to Tavneos.
US FDA warns of liver injury cases tied to Amgen's rare disease drug
The U.S. Food and Drug Administration on Monday said it had identified cases of liver injury in patients taking Amgen's drug for a group of rare autoimmune diseases and urged healthcare providers to...
REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha...
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
GSK and Amgen to add medicines to TrumpRx, Fox Business reports
GSK and Amgen will add their medicines to TrumpRX, the prescription drug website launched by President Donald Trump's administration, Fox Business reported on Friday.
Amgen: MariTide And Osteoporosis Sales Fuel The Rally
Despite the war in the Middle East, Amgen is trading near its 52-week high. One of the reasons is the strong growth in sales of its flagships in the oncology and cardiovascular franchises. So, Imdellt...
Amgen Inc. (AMGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
Amgen Inc. (AMGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., March 5, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Leerink Partners 2026 Global Healthcare Conference at 9:20 a.m.
AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
THOUSAND OAKS, Calif., March 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the second quarter of 2026.
Amgen Inc. (AMGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Amgen Inc. (AMGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
The High Dividend Yield Bull Market: 3 Compelling 6% Yields
High-yield stocks are outperforming, with a clear rotation from growth to value driving strong returns for dividend-focused investors. Safe, high-yielding companies are still trading at discounts. The...
10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.7% yield and -10% NAV discount. Selections emphasize sector diversifica...
AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
THOUSAND OAKS, Calif., Feb. 24, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 46th Annual TD Cowen Health Care Conference at 1:10 p.m.
Harbor Large Cap Value Fund Q4 2025 Portfolio Review
During the fourth quarter, the Harbor Large Cap Value Fund returned 1.26%, underperforming its benchmark, the Russell 1000® Value Index, which returned 3.81%, and underperforming the 2.66% return of t...
Amgen Inc. (AMGN) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
Amgen Inc. (AMGN) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
THOUSAND OAKS, Calif., Feb. 13, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2026 Virtual Oncology Leadership Summit at 12:15 p.m.
Prices, pipelines and patent cliffs: Inside pharma's big reset
Pharma earnings weren't the main focus for drugmakers this quarter. "2025 was about understanding kind of the rules of the future of the game," McKinsey Senior Partner Greg Graves told CNBC.
Amgen Inc. (AMGN) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
Amgen Inc. (AMGN) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists
CVS Health said on Thursday it would swap out Amgen and Eli Lilly's bone disease treatments for lower-cost alternatives in some of its preferred drug lists, starting April 1.
Why Amgen Stock Is Paying Off Big For Long-Term Investors
Amgen's (AMGN) decade-long commitment to shareholder value is underscored by a staggering $86 billion capital return program, a feat that firmly establishes the biotech giant as a premier player in th...